$NNVC

Novavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS), and Arcturus Therapeutics (ARCT) surged 20%, 7%, 14%, and 13% respectively, following a Russian lab worker's death. Retail investors speculated about potential government contracts. Other related stocks like Alpha Pro Tech (APT), Lakeland Industries (LAKE), and NanoViricides (NNVC) also rose. The WHO and U.S. officials downplayed the risk, but traders anticipated increased preparedness spending.

NanoViricides (NNVC) began Phase IIA of its NV-387 oral gummies trial for Ebola around Sept. 23, 2026, focusing on setting a tolerable dosing regimen before a Part IIB efficacy study. The company aims to establish a clear dosing regimen and initiate the randomized Part IIB with early efficacy signals.

NANOVIRICIDES, INC. (NNVC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Compensatory Arrangements of Certain Officers. Extension Employment Agreement - Anil Diwan On September 25, 2026, NanoViricides, Inc. (the “Registrant”) entered into an Extension Agreement effective July 1, 2026 (the “Diwan Extension”) of the Employment Agreement with

NanoViricides (NNVC) began Phase II trials of NV-387, a potential monkeypox treatment, in the DRC. The trial, led by Prof. Vivi Maketa, aims to assess safety and efficacy. NV-387 could address unmet needs, as current treatments like tecovirimat and brincidofovir have limitations. Success may position NV-387 for pandemic preparedness and FDA approval, with potential stockpiling contracts.

NANOVIRICIDES, INC. (NNVC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering New York, July 24, 2026 — NanoViricides, Inc. (NYSE American: NNVC) (“NanoViricides” or the “Company”), a clinical stage, leading global pioneer in the development of broad-spectrum antiviral

NanoViricides (NYSE American: NNVC) priced a registered direct offering with a single institutional investor for gross proceeds of about $3.8 million. The company will sell 2,516,339 shares, or pre-funded warrants, plus warrants for the same number of shares at a $1.75 exercise price, expiring about 5.5 years. Closing is expected around July 27, 2026.

NANOVIRICIDES, INC. (NNVC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 tm2620770d1_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 NANOVIRICIDES, INC. Common Stock (par value $0.00001 per share) At Market Issuance Sales Agreement July 17, 2026 D. Boral Capital LLC 590 Madison Avenue, 39 th Floor New York, New York 10022 Ladies and Gentlemen: NanoViricide

NanoViricides, Inc. (NNVC) said an independent analyst at Noble Capital Markets initiated coverage with an “Outperform” rating and a $6.00 target price, based on its estimates. The company also published a “Fireside Chat” interview with President Anil Diwan discussing NV-387, other programs, and FDA orphan drug and rare pediatric disease designation topics.

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).

NanoViricides highlights the urgent need for broad-spectrum antivirals, especially during the current severe influenza season dominated by the H3N2 variant, against which seasonal vaccines are less effective. The company's drug candidate, NV-387, is presented as a promising solution due to its broad-spectrum efficacy against influenza, RSV, and Coronaviruses, operating through a mechanism that viruses are unlikely to escape. NV-387 is currently in Phase II clinical trials and is being positioned as a potential first-line empiric therapy for respiratory viral infections.